NICE Backs Takeda’s Adcetris for Rare Lymphoma

July 13, 2020

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Takeda’s Adcetris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for treatment of adults with untreated systemic anaplastic large cell lymphoma.

NICE noted that patients treated with the combination lived longer and had a later disease progression than those treated with another combination chemotherapy — cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).

The agency said Adcetris is likely to be cost-effective for use by the National Health Service for treatment of the rare lymphoma.

View today's stories